Carmona Jose 4

What Happened Jose Carmona, Chief Financial Officer of ADC Therapeutics (ADCT), received a grant of 271,600 restricted share units (RSUs) on 2026-02-13 valued at $3.99 each (aggregate $1,083,684). On the same date 25,880 shares were withheld by the company at $3.99/share (~$103,261) to satisfy tax withholding obligations related to previously vested RSUs. The grant is an equity award (not an open-market purchase or sale).

Key Details

• Transaction date: February 13, 2026. Report filed Feb 18, 2026 (check filing timeliness — appears later than the typical two-business-day Form 4 window).
• Grant: 271,600 RSUs @ $3.99 | Notional value ≈ $1,083,684.
• Tax withholding: 25,880 shares withheld @ $3.99 | Value ≈ $103,261 (reported as a disposition for tax withholding).
• Shares owned after transaction: not specified in the details provided here — see the full Form 4 for total holdings.
• Footnotes:
  • F1: The 271,600 RSUs are to be delivered in settlement of an RSU award that vests one‑third on the first anniversary of the grant (Feb 13, 2027) and one‑third on each anniversary thereafter, subject to continued service.
  • F2: The 25,880 shares were withheld by the issuer to satisfy the reporting person’s tax withholding obligations on vested RSUs.

Context This filing reflects an equity award (RSUs) being granted and routine tax-withholding via share retention. Grants like this are compensation, not open-market purchases or sales; withholding of shares to meet tax obligations is common and does not necessarily indicate a trading decision by the insider.